 |
217 Diseases |  |
226 Trials |
|
226 Trials |  |
3828 News |  |
| «12...910111213141516171819...4950» |
- | capecitabine / Generic mfg., docetaxel / Generic mfg.
Trial suspension, Trial primary completion date: Trial of Neoadjuvant Docetaxel (clinicaltrials.gov) - Apr 20, 2022
P2, N=170, Suspended, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting --> Suspended | Trial primary completion date: Dec 2021 --> Dec 2022
- | Journal, MRI: Focal white matter microstructural alteration after anthracycline-based systemic treatment in long-term breast cancer survivors: a structural magnetic resonance imaging study. (Pubmed Central) - Apr 19, 2022
No significant difference was observed in the GM volume between groups. Our results suggest that microstructural abnormalities of certain vulnerable WM regions in the AST regimen-exposed brain may provide neuroimaging evidence for the identification of brain injury and cognitive impairment induced by specific chemotherapy regimens.
- | mitomycin / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie (Pubmed Central) - Apr 19, 2022
The implementation of an adjuvant epirubicin treatment protocol presented a good feasibility with low toxicity, without modifying the organization of the patients' care pathway. In the context of unpredictable mitomycin shortage, epirubicin represents a good therapeutic alternative in the endovesical adjuvant treatment of intermediate-risk NMIBC.
- | mitomycin / Generic mfg., epirubicin / Generic mfg.
Journal: Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer (Pubmed Central) - Apr 19, 2022
In the context of unpredictable mitomycin shortage, epirubicin represents a good therapeutic alternative in the endovesical adjuvant treatment of intermediate-risk NMIBC. The delivery of intravesical instillations of mitomycin C, epirubicin and BCG should follow a standardized procedure for better efficacy and lower morbidity.
- | epirubicin / Generic mfg.
Journal: A Turn-ON fluorometric biosensor based on ssDNA immobilized with a metal phenolic nanomaterial for the sequential detection of Pb(ii) and epirubicin cancer drug. (Pubmed Central) - Apr 19, 2022
Accordingly, the Turn-ON fluorescent probe had subsequent limits of detection of 1.5 and 5.6 nM for Pb and Epn, respectively. Hence, the reported NMc-CuTA-based sensing platform has potential applications for the detection of Pb and Epn in real samples with good sensitivity and selectivity.
- || Review, Journal: Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas. (Pubmed Central) - Apr 19, 2022
Delineating the contribution of metabolic pathways to tumor differentiation, progression, and resistance to different drugs is also the focus of research. The present review discusses the changes in glucose and fatty acid pathways associated with the most frequently applied chemotherapeutic drugs in breast cancer, as well the underlying molecular mechanisms and corresponding novel therapeutic strategies.
- | cisplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Primary poorly differentiated carcinoma of the vagina with focal neuroendocrine differentiation: a tumour with aggressive behaviour. (Pubmed Central) - Apr 17, 2022
For this rare tumour, cisplatin-based CCRT followed by IEP protocol adjuvant chemotherapy may have a limited treatment effect. Further studies are necessary to provide more information on clinical management.
- | doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg., idarubicin hydrochloride / Generic mfg.
Journal: Transcriptome analysis of long noncoding RNAs reveals their potential roles in anthracycline-induced cardiotoxicity. (Pubmed Central) - Apr 14, 2022
This study revealed several lncRNAs that can be potential biomarkers or targets for further ANT-induced cardiotoxicity investigation, according to the transcriptome in both human cardiac microtissues expose to ANTs as well as in heart biopies form ANT-treated patients. Especially, H19 lncRNA showed its contribution to on-target toxicity, in which it is involved in both chemoresistance and cardiotoxic mechanism.
- | epirubicin / Generic mfg.
Journal, Synthetic lethality: Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation. (Pubmed Central) - Apr 13, 2022
Targeting PACMP alone inhibits tumor growth by causing a synthetic lethal interaction between CtIP and PARP inhibitions and confers sensitivity to PARP/ATR/CDK4/6 inhibitors, ionizing radiation, epirubicin, and camptothecin. Our findings reveal that a lncRNA-derived micropeptide regulates cancer progression and drug resistance by modulating DDR, whose inhibition could be employed to augment the existing anticancer therapeutic strategies.
- | Journal: MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. (Pubmed Central) - Apr 13, 2022
P3
It had no prognostic value in node-negative patients, but there was a clear association in node-positive patients. Post-chemotherapy CA27.29 assessment did not add any prognostic value, either on its own or in addition to pre-chemotherapy CA27.29 assessment.
- | epirubicin / Generic mfg.
Journal: Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. (Pubmed Central) - Apr 12, 2022
We also show that biological targeting, either through radiotherapy or EGFR, is critical to the therapeutic effects of nanoengagers. Last, EGFR-targeted nanoengagers can augment both NK-activating agents and chemotherapy (epirubicin) as highly effective anticancer agents, providing robust chemoimmunotherapy.
- || Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Review, Journal, PD(L)-1 Biomarker, IO biomarker: Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks. (Pubmed Central) - Apr 9, 2022
This and 3 other case reports of disparate PD-L1 expression demonstrate complete responses in PD-L1 positive MPNSTs treated with ICT. These case reports necessitate further study of ICT in neural crest cell subtype of STS.
- | epirubicin / Generic mfg.
Journal: Development of novel aptamer-based targeted chemotherapy for bladder cancer. (Pubmed Central) - Apr 8, 2022
As proof of principle, a B1-guided DNA nanotrain delivery vehicle for epirubicin was constructed as a targeted intravesical chemotherapy...The B1-nanotrain-epirubicin construct exhibited selective cytotoxicity towards bladder cancer cells and outperformed epirubicin in murine orthotopic xenograft models of human bladder cancer. This aptamer-based delivery system makes targeted chemotherapy possible for bladder cancer, providing a compelling rationale for clinical development.
- ||| Arokaris (fosnetupitant) / Helsinn, Otsuka, netupitant (Ro 67-3189) / Helsinn, Otsuka
Clinical, P3 data, Journal: A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. (Pubmed Central) - Apr 7, 2022
This aptamer-based delivery system makes targeted chemotherapy possible for bladder cancer, providing a compelling rationale for clinical development. FosNTP demonstrated a favorable safety profile with a very low risk of ISRs in the AC/EC setting.
- | Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: B-IMMUNE: Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (clinicaltrials.gov) - Apr 7, 2022
P1/2, N=57, Recruiting, Sponsor: Grand H
FosNTP demonstrated a favorable safety profile with a very low risk of ISRs in the AC/EC setting. Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
- | metformin / Generic mfg.
Trial termination: NeoMET Study in Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Apr 6, 2022
P2, N=92, Terminated, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023 Active, not recruiting --> Terminated; Slow enrollment.
- | Enrollment open: Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients (clinicaltrials.gov) - Apr 6, 2022
P1/2, N=46, Recruiting, Sponsor: Peking University People's Hospital
Active, not recruiting --> Terminated; Slow enrollment. Not yet recruiting --> Recruiting
- || capecitabine / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. (Pubmed Central) - Apr 5, 2022
Not yet recruiting --> Recruiting Addition of capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer.
- || Clinical, Journal: Wipe-sampling procedure optimisation for the determination of 23 antineoplastic drugs used in the hospital pharmacy. (Pubmed Central) - Apr 2, 2022
Addition of capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer. Wipe sampling method was successfully developed and applied to real samples to determine surface contamination with 23 antineoplastic agents in trace amounts.
- | Enrollment closed, Trial completion date, Trial primary completion date: TOPGEAR: Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma (clinicaltrials.gov) - Apr 1, 2022
P2/3, N=574, Active, not recruiting, Sponsor: Australasian Gastro-Intestinal Trials Group
Wipe sampling method was successfully developed and applied to real samples to determine surface contamination with 23 antineoplastic agents in trace amounts. Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2026 | Trial primary completion date: Dec 2020 --> Dec 2026
- | carboplatin / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Trial primary completion date: TCTN: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer (clinicaltrials.gov) - Mar 31, 2022
P3, N=970, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2026 | Trial primary completion date: Dec 2020 --> Dec 2026 Trial primary completion date: Jun 2021 --> Dec 2022
- ||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (clinicaltrials.gov) - Mar 31, 2022
P2, N=216, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Jun 2021 --> Dec 2022 Recruiting --> Active, not recruiting
- | epirubicin / Generic mfg.
Journal: The impact of COVID-19 on cardio-oncology care in Taiwan. (Pubmed Central) - Mar 31, 2022
Notably, none of the enrolled patients reported MACEs during the COVID pandemic. We observed an impact of anxiety on patients receiving epirubicin but it did not influence their return ratio.
- || docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen. (Pubmed Central) - Mar 31, 2022
Chemotherapy drugs increase the risk of atherosclerotic cardiovascular disease in breast cancer patients. It is necessary to strengthen interdisciplinary cooperation to dynamic assess the cardiovascular health of patients of breast cancer patients.
- | Trial completion date, Trial primary completion date: Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study (clinicaltrials.gov) - Mar 31, 2022
P=N/A, N=20, Recruiting, Sponsor: Institut de cancérologie Strasbourg Europe
It is necessary to strengthen interdisciplinary cooperation to dynamic assess the cardiovascular health of patients of breast cancer patients. Trial completion date: Feb 2022 --> Sep 2022 | Trial primary completion date: Feb 2022 --> Sep 2022
- | cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Journal: Severe hyponatraemia in two patients with breast cancer caused by low-dose cyclophosphamide and precipitated by aprepitant. (Pubmed Central) - Mar 30, 2022
This is a typical case of a rare cause of a common medical problem. A systematic approach to diagnosis and treatment of hyponatraemia in an oncology patient requires awareness of toxicities of systemic anticancer agents.
- | epirubicin / Generic mfg.
Journal: Flexible Organic Framework-Based Anthracycline Prodrugs for Enhanced Tumor Growth Inhibition. (Pubmed Central) - Mar 29, 2022
Laser confocal scanning microscopy and flow cytometric analysis support that FOF-hz displays enhanced permeability and retention effect, which helps to overcome the multidrug resistance of MCF-7/ADR tumor cells and leads to enhanced cytotoxicity for MCF-7/ADR cells. In vivo studies reveal a considerable improvement of the efficacy of the prodrug FOF-DOX for the inhibition of the growth of the MCF-7/ADR tumor.
- | epirubicin / Generic mfg.
Journal: Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas. (Pubmed Central) - Mar 29, 2022
In tumor-bearing rats after applying multifunctional targeting liposomes, the median survival time was evidently observed as being markedly longer than other controls. The epirubicin plus resveratrol liposomes modified with WGA and MAN exhibited strong ability to improve epirubicin and resveratrol transporting across the BBB and therapeutic effect on brain glioma, showing multifunctional targeting capability.
- | epirubicin / Generic mfg.
Preclinical, Journal: The Fate of Sialic Acid and PEG Modified Epirubicin Liposomes in Aged versus Young Cells and Tumor Mice Models. (Pubmed Central) - Mar 27, 2022
Accordingly, 8-month-old mice treated with EPI-SL achieved the best therapeutic effect at different ages and with different liposomes. EPI-SL could improve the antitumor effect of 8-week-old and 8-month-old mice.
- ||| Journal, Adverse events: Sexual and fertility-related adverse effects of medicinal treatment for cancer; a national evaluation among medical oncologists. (Pubmed Central) - Mar 26, 2022
Results revealed that oncologists have different beliefs about possible sexual and fertility-related adverse effects concerning medication resources and literature. Based on our results, oncologists do not possess sufficient knowledge to inform patients about sexual and fertility-related adverse effects.
- | epirubicin / Generic mfg.
Journal: CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis. (Pubmed Central) - Mar 25, 2022
CircEAF2 counteracted EBV + DLBCL progression via miR-BART19-3p/APC/β-catenin axis, referring circEAF2 as a potential prognostic biomarker. Therapeutic targeting EBV-encoded miRNA may be a promising strategy in treating EBV-associated lymphoid malignancies.
- | cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
New trial: EMEG-ECDD: Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration (clinicaltrials.gov) - Mar 25, 2022
P=N/A, N=100, Not yet recruiting, Sponsor: Centre Georges Francois Leclerc
- | cisplatin / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Journal: Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. (Pubmed Central) - Mar 24, 2022
Therapeutic targeting EBV-encoded miRNA may be a promising strategy in treating EBV-associated lymphoid malignancies. In terms of surgical complications, FLOT and ECX/ECF were equally safe in patients undergoing resection for OG adenocarcinoma.
- | epirubicin / Generic mfg.
Journal: Computational and Experimental Protocols to Study Cyclo-dihistidine Self- and Co-assembly: Minimalistic Bio-assemblies with Enhanced Fluorescence and Drug Encapsulation Properties. (Pubmed Central) - Mar 24, 2022
Our published studies on the self- and co-assembly of cyclo-HH peptides demonstrated their capacity to coordinate with Zn(II), their enhanced photoluminescence and their ability to self-encapsulate epirubicin, a chemotherapy drug...We outline the experimental protocols, which involve fluorescence spectroscopy, transmission electron microscopy, and atomic force microscopy protocols, as well as the computational protocols, which involve structural and energetic analysis of the assembled nanostructures. We suggest that the computational and experimental methods presented here can be generalizable, and thus can be applied in the investigation of self- and co-assembly systems involving other short peptides, encapsulating compounds and binding to ions, beyond the particular ones presented here.
- | epirubicin / Generic mfg.
Journal: Successful treatment of hemophagocytic syndrome in a patient with T cell lymphoma, EBV infection, and bone marrow necrosis: A case report. (Pubmed Central) - Mar 23, 2022
Cyclophosphamide, epirubicin, vincristine, glucocorticoid remains an effective regimen for the treatment of T-cell LAPS. This study provides a better understanding of the diagnosis and treatment of LAPS.
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL (clinicaltrials.gov) - Mar 21, 2022
P2, N=48, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC) (Exhibition area) - Mar 19, 2022 - Abstract #ESMOBC2022ESMO_BC_295;
P2
Social/family and emotional aspects were not affected by the regime.Conclusions nP q1w led to a significantly higher pCR rate but is associated with decreased QoL compared to nP d1,8 q3w, which is consistent with the higher toxicity reported for nP q1w. Benefit and risks need to be discussed with the pts.
- | epirubicin / Generic mfg.
Journal: Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis. (Pubmed Central) - Mar 19, 2022
Finally, in mice bearing MDA-MB-231 cell xenografts, co-administration of CEP (12 mg/kg, ip, once every other day for 36 days) greatly enhanced the therapeutic efficacy of epirubicin (2 mg/kg) as compared with administration of either drug alone. Taken together, our results implicate that a combination of cepharanthine with chemotherapeutic agents could represent a novel therapeutic strategy for the treatment of breast cancer.
- || carboplatin / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: A case of metastatic eccrine porocarcinoma without actionable mutations treated with carboplatin and epirubicin chemotherapy. (Pubmed Central) - Mar 18, 2022
Taken together, our results implicate that a combination of cepharanthine with chemotherapeutic agents could represent a novel therapeutic strategy for the treatment of breast cancer. No abstract available
- ||| albumin-bound paclitaxel / Generic mfg.
New trial, Real-world evidence, Real-world: Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study (clinicaltrials.gov) - Mar 17, 2022
P=N/A, N=500, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- || Retrospective data, Review, Journal: The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis. (Pubmed Central) - Mar 17, 2022
Docetaxel combined with cisplatin and fluorouracil induction regimen provided the first exact probability of efficacy in term of local recurrence-free survival, ranking second in OS, but accompanied by the highest rates of grade 3 or above AEs. GP regimen appears to be currently the best choice of IC regimen for combined benefit of patients with locally advanced NPC.
- | epirubicin / Generic mfg.
Journal: Risk factors and early cardiovascular outcomes in cancer patients treated with anthracycline-based chemotherapy in Tanzania: a protocol for a quasi-experimental study. (Pubmed Central) - Mar 17, 2022
P-values <0.05 will be considered statistically significant. The results of this study will help clinicians and policymakers to understand the burden of early cardiovascular outcomes and plan for appropriate preventive strategies.
- | Journal: The regulation of autophagy by the miR-199a-5p/p62 axis was a potential mechanism of small cell lung cancer cisplatin resistance. (Pubmed Central) - Mar 17, 2022
The results of this study will help clinicians and policymakers to understand the burden of early cardiovascular outcomes and plan for appropriate preventive strategies. The regulation of autophagy by the miR-199a-5p/p62 axis was a potential mechanism of small cell lung cancer cisplatin resistance.
- | mitomycin / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Use of chemotherapy to treat hepatocellular carcinoma. (Pubmed Central) - Mar 16, 2022
Moreover, locoregional chemotherapy can be achieved with TACE and HAIC (possibly involving FOLFOX, DOX, mitomycin C, cisplatin, epirubicin, etc.)...Hence, this review summarizes large-scale trials and studies examining the development and innovative use of chemotherapeutic agents. Mounting clinical evidence warrants an exploration of the efficacy of chemotherapy.
- | epirubicin / Generic mfg.
Journal: Anthracycline derivatives inhibit cardiac CYP2J2. (Pubmed Central) - Mar 15, 2022
Herein, we performed biochemical studies to understand the interaction of anthracycline derivatives (daunorubicin, doxorubicin, epirubicin, idarubicin, 5-iminodaunorubicin, zorubicin, valrubicin, and aclarubicin) with CYP2J2...We determined that ebastine competitively inhibits anthracycline binding, suggesting that ebastine and anthracyclines may share the same binding site...Taken together, we use both experimental and theoretical methodologies to unveil the interactions of anthracycline derivatives with CYP2J2. These studies will help identify alternative mechanisms of how anthracycline cardiotoxicity may be mediated through the inhibition of cardiac P450, which will aid in the design of new anthracycline derivatives with lower toxicity.
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Mar 15, 2022
P3, N=4804, Active, not recruiting, Sponsor: Hoffmann-La Roche
These studies will help identify alternative mechanisms of how anthracycline cardiotoxicity may be mediated through the inhibition of cardiac P450, which will aid in the design of new anthracycline derivatives with lower toxicity. Trial completion date: Dec 2023 --> Nov 2028
- ||| Herceptin (trastuzumab) / Roche
Clinical, P3 data, Journal: Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. (Pubmed Central) - Mar 12, 2022
P3
Both groups received trastuzumab (6 mg/kg; loading dose 8 mg/kg) and pertuzumab (420 mg intravenously; loading dose 840 mg) every 3 weeks...Anthracycline use is associated with increased risk of febrile neutropenia, cardiotoxic effects, and secondary malignant neoplasms. ClinicalTrials.gov Identifier: NCT01996267.
- ||| zoledronic acid / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Clinical, P3 data, Journal: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. (Pubmed Central) - Mar 12, 2022
P3
The results of this phase 3 randomized clinical trial indicate that extending the zoledronate treatment beyond 2 years does not improve the prognosis of high-risk patients with early breast cancer receiving chemotherapy, suggesting that the currently recommended bisphosphonate treatment duration of 3 to 5 years could be reduced. ClinicalTrials.gov Identifier: NCT02181101.
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Retrospective data, Journal, Real-world evidence: The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study. (Pubmed Central) - Mar 9, 2022
ClinicalTrials.gov Identifier: NCT02181101. BV is a promising treatment in patients with ALCL, AITL and PTCL-TFH in frontline treatment settings.
- DR30303 / Zhejiang Doer Biologics
DR30303, a SMART-VHHBody powered anti-CLDN18.2 VHH-Fc with enhanced ADCC activity for the treatment of gastric and pancreatic cancers (Section 37) - Mar 9, 2022 - Abstract #AACR2022AACR_7084;
DR30303 also demonstrated favorable pharmacokinetic properties (t1/2~ 120 hours) and tolerable toxicities (MTD≥ 748.5 mg) in both SD rats and cynomolgus monkeys. Doer Biologics submitted IND to the NMPA in November 2021 and plans to initiate the Phase 1 clinical trial in H1 2022 upon IND approval.